SHARE
 
E. Jason Abel, MD, FACS close
BiumugHiAAA

E. Jason Abel, MD, FACS Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Abel is board certified by the American Board of Urology and specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers, including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

 

Dr. Abel performs open and laparoscopic surgery, including surgery using the daVinci robot. His philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Specialties

Clinics

University Hospital
(608) 263-4757 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship

Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX


Residency University of Utah Hospital, Salt Lake City, UT
Internship University of Utah Hospital, Salt Lake City, UT
Medical School University of Texas Medical School, Houston, TX

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Abel conducts clinical, translational and basic research in urologic oncology. He currently is involved in several projects focusing on the development and metastasis of kidney cancer.


PubMed Articles
Esdaille AR Abel EJ Editorial Comment. J Urol . 2021 Feb 24;:101097JU000000000000154901
[PubMed ID: 33625923]
Bade RM Schehr JL Emamekhoo H Gibbs BK Rodems TS Mannino MC Desotelle JA Heninger E Stahlfeld CN Sperger JM Singh A Wolfe SK Niles DJ Arafat W Steinharter JA Abel EJ Beebe DJ Wei XX McKay RR Choueri TK Lang JM Development and initial clinical testing of a multi-plexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. Mol Oncol . 2021 Feb 19;
[PubMed ID: 33604999]
Posielski NM Richards KA Liou JI Borza T Abel EJ Downs TM Jarrard DF Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients with Advanced Prostate Cancer: A Veterans Administration Cohort Study. Urology . 2021 Feb 12;
[PubMed ID: 33587939]
Curci NE Triche BL Abel EJ Bhutani G Maciolek KA Dreyfuss LD Allen GO Caoili EM Davenport MS Wells SA Effect of iodinated contrast material on post-operative eGFR when administered during renal mass ablation. Eur Radiol . 2021 Jan 25;
[PubMed ID: 33492471]
Dreyfuss LD Master VA Raman JD Spiess PE Wells SA Merrill SB Peyton CC Sankar D Sohl B Patil D Shapiro DD Allen GO Abel EJ Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma. Urology . 2020 Dec;146:152-157
[PubMed ID: 32781079]
Virumbrales-Muñoz M Chen J Ayuso J Lee M Abel EJ Beebe DJ Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials. Lab Chip . 2020 Nov 24;20(23):4420-4432
[PubMed ID: 33103699]
Rini B Abel EJ Albiges L Bex A Brugarolas J Bukowski RM Coleman JA Drake CG Figlin RA Futreal A Hammers H Powles T Rathmell WK Ricketts CJ Turajlic S Wood CG Leibovich BC Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. Clin Genitourin Cancer . 2020 Nov 14;
[PubMed ID: 33358149]
Wetley KA Abel EJ Dreyfuss LD Huang W Brace CL Wells SA CT and MR imaging surveillance of stage 1 renal cell carcinoma after microwave ablation. Abdom Radiol (NY) . 2020 Sep;45(9):2810-2824
[PubMed ID: 32715335]
Swietlik JF Knott EA Longo KC Abel EJ Wells SA Lubner MG Laeseke PF McCormick T Hinshaw JL Lee FT Jr Ziemlewicz TJ Microwave Ablation of Adrenal Tumors in Patients With Continuous Intra-Arterial Blood Pressure Monitoring Without Prior Alpha-Adrenergic Blockade: Safety and Efficacy. Cardiovasc Intervent Radiol . 2020 Sep;43(9):1384-1391
[PubMed ID: 32529338]
Shapiro DD Abel EJ Renal cell carcinoma with isolated lymph node metastases should be reclassified as stage IV. Cancer . 2020 Jul 1;126(13):2965-2967
[PubMed ID: 32329898]
Abel EJ Editorial Comment. J Urol . 2020 Mar;203(3):503
[PubMed ID: 31774732]
Miller BL Abel EJ Allen G Schumacher JR Jarrard D Downs T Richards KA Trends in epidural anesthesia use at the time of radical cystectomy and its association with perioperative and survival outcomes: a population-based analysis. Am J Clin Exp Urol . 2020;8(1):28-37
[PubMed ID: 32211451]
Peyton CC Abel EJ Chipollini J Boulware DC Azizi M Karam JA Margulis V Master VA Matin SF Raman JD Sexton WJ Wood CG Spiess PE The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus . 2020 Jan 15;6(1):104-111
[PubMed ID: 30206003]
Elmaraghi S Chen TJ Heckman JE Shiau JM Williams DH Abel EJ Afifi AM Functional penile replantation after traumatic avulsion amputation below the pubis: A case report. Microsurgery . 2020 Jan;40(1):70-73
[PubMed ID: 30714225]
Kim NY Lubner MG Nystrom JT Swietlik JF Abel EJ Havighurst TC Silverman SG McGahan JP Pickhardt PJ Utility of CT Texture Analysis in Differentiating Low-Attenuation Renal Cell Carcinoma From Cysts: A Bi-Institutional Retrospective Study. AJR Am J Roentgenol . 2019 Dec;213(6):1259-1266
[PubMed ID: 31386573]
Dreyfuss LD Wells SA Best SL Hedican SP Ziemlewicz TJ Lubner MG Hinshaw JL Lee FT Jr Nakada SY Abel EJ Development of a Risk-stratified Approach for Follow-up Imaging After Percutaneous Thermal Ablation of Sporadic Stage One Renal Cell Carcinoma. Urology . 2019 Dec;134:148-153
[PubMed ID: 31465794]
Maciolek KA Abel EJ Posielski NM Hinshaw JL Lubner MG Lee FT Jr Ziemlewicz TJ Wells SA Tumor location does not impact oncologic outcomes for percutaneous microwave ablation of clinical T1a renal cell carcinoma. Eur Radiol . 2019 Nov;29(11):6319-6329
[PubMed ID: 31016448]
Flack CK Calaway AC Miller BL Picken MM Gondim DD Idrees MT Abel EJ Gupta GN Boris RS Comparing oncologic outcomes in patients undergoing surgery for oncocytic neoplasms, conventional oncocytoma, and chromophobe renal cell carcinoma. Urol Oncol . 2019 Nov;37(11):811.e17-811.e21
[PubMed ID: 31451335]
Olson MC Abel EJ Mankowski Gettle L Contrast-Enhanced Ultrasound in Renal Imaging and Intervention. Curr Urol Rep . 2019 Oct 17;20(11):73
[PubMed ID: 31624973]
Shapiro DD Abel EJ Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors. Curr Opin Urol . 2019 Sep;29(5):513-520
[PubMed ID: 31305274]